Pfizer and BioNTech Start Phase 1/2 Study of First mRNA-based Shingles Vaccine in the US
Pfizer and BioNTech plan to use mRNA technology to meet the demand for highly effective, well-tolerated, and effectively manufactured shingles
Read morePfizer and BioNTech plan to use mRNA technology to meet the demand for highly effective, well-tolerated, and effectively manufactured shingles
Read moreFrench clinical-stage biotech company Sensorion, which focuses on the creation of cutting-edge treatments to manage, prevent, and reverse hearing loss
Read morePfizer Inc. (NYSE: PFE) announced in late December, positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene
Read moreApogenix, a biopharmaceutical company developing next-gen immunotherapeutics, announced on Wednesday that asunercept showed statistically meaningful benefits for hospitalized COVID-19 patients
Read moreMachine learning tissue classifiers are one of the most powerful and promising AI-based clinical research solutions for all types of
Read moreThe first doses of an experimental HIV vaccine antigen have been provided in a clinical study at George Washington University
Read moreA next-generation COVID-19 vaccine, developed by British biotech Emergex, designed to prime T-Cells to rapidly remove viral-infected cells and offer
Read moreNew Phase 3 Data has shown a positive correlation between the human monoclonal antibody ADUHELM™ treatment effect on biomarkers and
Read moreThe novel COVID-19 investigational oral antiviral treatment PAXLOVID™ (PF-07321332; ritonavir) by Pfizer, was found to reduce the risk of hospitalization
Read moreRhizen Pharmaceuticals has started dosing in a phase I/Ib trial to assess the efficiency of PARP inhibitor (RP12146) in advanced
Read more